KR20120032523A - 4-메틸피라졸을 사용하여 인간 대상을 치료하기 위한 유전자형 특이적 방법 - Google Patents

4-메틸피라졸을 사용하여 인간 대상을 치료하기 위한 유전자형 특이적 방법 Download PDF

Info

Publication number
KR20120032523A
KR20120032523A KR1020127000590A KR20127000590A KR20120032523A KR 20120032523 A KR20120032523 A KR 20120032523A KR 1020127000590 A KR1020127000590 A KR 1020127000590A KR 20127000590 A KR20127000590 A KR 20127000590A KR 20120032523 A KR20120032523 A KR 20120032523A
Authority
KR
South Korea
Prior art keywords
subject
adh2
ethanol
acetaldehyde
alcohol dehydrogenase
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020127000590A
Other languages
English (en)
Korean (ko)
Inventor
토마스 이 데일리
엘리자베스 씨 스콰이어스
킨훙 페오니 유
Original Assignee
랩터 세라퓨틱스 인크.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 랩터 세라퓨틱스 인크. filed Critical 랩터 세라퓨틱스 인크.
Publication of KR20120032523A publication Critical patent/KR20120032523A/ko
Ceased legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Otolaryngology (AREA)
  • Toxicology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
KR1020127000590A 2009-06-10 2010-06-09 4-메틸피라졸을 사용하여 인간 대상을 치료하기 위한 유전자형 특이적 방법 Ceased KR20120032523A (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US18588409P 2009-06-10 2009-06-10
US61/185,884 2009-06-10

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1020147029368A Division KR20140138318A (ko) 2009-06-10 2010-06-09 4-메틸피라졸을 사용하여 인간 대상을 치료하기 위한 유전자형 특이적 방법

Publications (1)

Publication Number Publication Date
KR20120032523A true KR20120032523A (ko) 2012-04-05

Family

ID=43309203

Family Applications (3)

Application Number Title Priority Date Filing Date
KR1020127000590A Ceased KR20120032523A (ko) 2009-06-10 2010-06-09 4-메틸피라졸을 사용하여 인간 대상을 치료하기 위한 유전자형 특이적 방법
KR1020147029368A Ceased KR20140138318A (ko) 2009-06-10 2010-06-09 4-메틸피라졸을 사용하여 인간 대상을 치료하기 위한 유전자형 특이적 방법
KR1020167023761A Ceased KR20160147709A (ko) 2009-06-10 2010-06-09 4-메틸피라졸을 사용하여 인간 대상을 치료하기 위한 유전자형 특이적 방법

Family Applications After (2)

Application Number Title Priority Date Filing Date
KR1020147029368A Ceased KR20140138318A (ko) 2009-06-10 2010-06-09 4-메틸피라졸을 사용하여 인간 대상을 치료하기 위한 유전자형 특이적 방법
KR1020167023761A Ceased KR20160147709A (ko) 2009-06-10 2010-06-09 4-메틸피라졸을 사용하여 인간 대상을 치료하기 위한 유전자형 특이적 방법

Country Status (13)

Country Link
US (4) US20120252857A1 (enExample)
EP (2) EP2440049B1 (enExample)
JP (2) JP5836270B2 (enExample)
KR (3) KR20120032523A (enExample)
CN (2) CN102458121A (enExample)
AU (1) AU2010258821B2 (enExample)
DK (1) DK2440049T3 (enExample)
ES (1) ES2656489T3 (enExample)
NO (1) NO2440049T3 (enExample)
PT (1) PT2440049T (enExample)
SG (1) SG176734A1 (enExample)
TW (1) TWI523653B (enExample)
WO (1) WO2010144518A1 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8901484B2 (en) * 2012-04-27 2014-12-02 Sanofi-Aventis Deutschland Gmbh Quantification of impurities for release testing of peptide products
JP6421249B2 (ja) * 2015-10-26 2018-11-07 株式会社日立製作所 デバッグを支援する方法及び計算機システム
WO2019209123A1 (en) * 2018-04-27 2019-10-31 Remedius Biotech Limited Diagnosis, risk reduction and treatment of conditions associated with elevated aldehyde levels
CN109381458B (zh) * 2018-12-16 2020-09-01 李志武 甲吡唑及其盐在制备抗癫痫药物中的用途
AU2023402122A1 (en) * 2022-12-01 2025-06-12 PICOENTECH Co., LTD. Novel aldehyde dehydrogenase food and drug composition for improving behavior and motor function
WO2024117701A1 (en) * 2022-12-01 2024-06-06 PICOENTECH Co., LTD. Food and drug composition containing novel aldehyde dehydrogenase for suppressing tremor or movement disorder
WO2024117698A1 (en) * 2022-12-01 2024-06-06 PICOENTECH Co., LTD. Food and pharmaceutical composition for detoxifying endogenous aldehydes

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS57106620A (en) 1980-12-22 1982-07-02 Takara Shuzo Co Ltd Ameliorant for alcoholic metabolism
GB0404481D0 (en) 2004-02-28 2004-03-31 Rhodia Cons Spec Ltd Soap control agent
US20080021083A1 (en) * 2004-03-03 2008-01-24 Daley Thomas E 4-Methylpyrazole Formulations for Inhibiting Ethanol Intolerance
US20090117079A1 (en) * 2007-11-02 2009-05-07 Monte Woodrow C Methods and materials for treating or preventing diseases/disorders mediated by alcohol dehydrogenase

Also Published As

Publication number Publication date
TW201110966A (en) 2011-04-01
EP2440049B1 (en) 2017-12-13
SG176734A1 (en) 2012-01-30
EP2440049A1 (en) 2012-04-18
JP5836270B2 (ja) 2015-12-24
CN106943398A (zh) 2017-07-14
AU2010258821B2 (en) 2016-03-10
US20180098964A1 (en) 2018-04-12
CN102458121A (zh) 2012-05-16
TWI523653B (zh) 2016-03-01
US20120252857A1 (en) 2012-10-04
PT2440049T (pt) 2018-03-05
NO2440049T3 (enExample) 2018-05-12
WO2010144518A1 (en) 2010-12-16
AU2010258821A1 (en) 2012-01-19
EP2440049A4 (en) 2012-12-05
ES2656489T3 (es) 2018-02-27
US20120322843A1 (en) 2012-12-20
KR20160147709A (ko) 2016-12-23
JP2015155422A (ja) 2015-08-27
JP2012529526A (ja) 2012-11-22
EP3311811A1 (en) 2018-04-25
DK2440049T3 (en) 2018-02-19
US20170007578A1 (en) 2017-01-12
KR20140138318A (ko) 2014-12-03

Similar Documents

Publication Publication Date Title
US20170007578A1 (en) Genotype Specific Methods for Treating Human Subjects Using 4-Methylpyrazole
EP2768507B1 (en) Biomarkers predictive of responsiveness to alpha 7 nicotinic acetylcholine receptor activator treatment
EP4005570B1 (en) Pridopidine for use in treating rett syndrome
EA017484B1 (ru) Селективный антагонист опиоидных рецепторов каппа
US20220162610A1 (en) Novel rna transcript
US20230242909A1 (en) Methods and compositions for neuroprotection
WO2014091388A2 (en) Biomarker predictive of responsiveness to alpha 7 nicotinic acetylcholine receptor activator treatment
Cho et al. The MATE1 rs2289669 polymorphism affects the renal clearance of metformin following ranitidine treatment
US20160243082A1 (en) 4-Methylpyrazole Formulations for Inhibiting Ethanol Intolerance
WO2005112906A2 (en) Method for augmenting the effects of serotonin reuptake inhibitors
EP2801625B1 (en) Molecular genetic approach to treatment and diagnosis of alcohol and drug dependence
EP3119388B1 (en) Carboxy-cyclopropyl undecanol compounds for treatment of liver disease and other medical disorders
US20050203169A1 (en) Methods and compositions for treating diseases associated with excesses in ACE
CN110664815B (zh) 长春花碱iii在制备预防或治疗阿尔茨海默症药物中的应用
CN117396209A (zh) 用于预防或治疗肌肉疾病的包含桦褐孔菌醇的组合物
HK1168993A (en) Genotype specific methods for treating human subjects using 4-methylpyrazole
HK1168993B (en) Genotype specific methods for treating human subjects using 4-methylpyrazole
WO2013139700A1 (en) Memory genes
FR2896690A1 (fr) Utilisation de l'enantiomere(s) de la mequitazine pour la preparation d'un medicament, tout en limitant la toxicite genomique
Martinez Genetic variation of the beta-2 adrenergic receptor and the phenylethanolamine N-methyltransferase enzyme: Influence on catecholamines, cardiovascular regulation, and the cardiopulmonary response to albuterol
HK40009961B (en) Use of pridopidine for treating rett syndrome

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20120109

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20121005

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20131223

Patent event code: PE09021S01D

E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20140917

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20131223

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I

A107 Divisional application of patent
J201 Request for trial against refusal decision
PA0104 Divisional application for international application

Comment text: Divisional Application for International Patent

Patent event code: PA01041R01D

Patent event date: 20141020

PJ0201 Trial against decision of rejection

Patent event date: 20141020

Comment text: Request for Trial against Decision on Refusal

Patent event code: PJ02012R01D

Patent event date: 20140917

Comment text: Decision to Refuse Application

Patent event code: PJ02011S01I

Appeal kind category: Appeal against decision to decline refusal

Appeal identifier: 2014101006456

Request date: 20141020

J301 Trial decision

Free format text: TRIAL DECISION FOR APPEAL AGAINST DECISION TO DECLINE REFUSAL REQUESTED 20141020

Effective date: 20160331

PJ1301 Trial decision

Patent event code: PJ13011S01D

Patent event date: 20160331

Comment text: Trial Decision on Objection to Decision on Refusal

Appeal kind category: Appeal against decision to decline refusal

Request date: 20141020

Decision date: 20160331

Appeal identifier: 2014101006456